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Abstract
Background: Graft right ventricular (RV) function is compromised directly posttransplant, especially in heart transplantation (HTx) recipients
with pretransplant pulmonary hypertension (PH). Graft RV size and systolic function, and the effect of the recipient’s pulmonary haemodynamics
on the graft extracellular matrix are not well characterised in the patients long-term after HTx. Aim: Comparison of RV size and systolic function
in HTx recipients’ long-term posttransplant stratified by the presence of pretransplant PH.Methods: HTx survivors2 years posttransplant were
divided into group I without pretransplant PH (pulmonary vascular resistance, PVR<2.5 Wood units, n = 37) and group II with PH (PVR2.5 Wood
units, n = 16). RV size and systolic function weremeasured using cardiacmagnetic resonance imaging (CMR). The collagen content was assessed in
septal endomyocardial biopsies obtained at HTx and at study inclusion. Results: Mean posttransplant follow-up was 5.2  2.9 years (group I) and
4.9  2.2 years (group II) ( p = 0.70). PVR was 1.5  0.6 vs 4.1  1.7 Wood units pretransplant ( p < 0.001), and 1.2  0.5 vs 1.3  0.5 Wood units
at study inclusion (p = 0.43). Allograft RV size and systolic function were similar in both groups (p always 0.07). Collagen content at
transplantation and at follow-up were not different (p always0.60). Conclusion: Posttransplant normalisation of pretransplant PH is associated
with normal graft RV function long-term after HTx.
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doi:10.1016/j.ejcts.2009.05.021circulationof the recipient. Especially in candidateswithmore
severe PH, the risk for acute RV failure and early postoperative
death is increased [4—9]. However, postoperative mortality is
not increased in HTx recipients with mild-to-moderate
pretransplant PH [5,9—12] warranting the acceptance of
these patients as HTx candidates [3]. Nevertheless, more
episodes of acute RV failure occur within the first 30
postoperative days in these patients [1,10]. In addition,
dilatation and decreased systolic function of the graft RV are
observed after the first postoperative year [13—15].
Pulmonary artery pressures normalise within the first 2
years after HTx in most recipients with pretransplant PH
[10,12,16,21]. Because of the well-known interdependency
of RV size and function and pulmonary artery pressure, we
hypothesised that normalisation of graft RV size and function
may occur after this time interval. This hypothesis was tested
by recruiting HTx recipients who were more than 2 years
posttransplant. In fact, pulmonary haemodynamics was
similar in these study participants irrespective of the
presence or absence of pretransplant PH. This permitted
measurements of graft RV size and systolic function on a
similar haemodynamic background.1. Introduction
Heart transplantation (HTx) remains the most effective
therapy for well-selected patients with severe congestive
heart failure (CHF). With optimal medical treatment, CHF
symptoms often may not worsen before the development of
pulmonary hypertension (PH) [1,2]. This may explain the
increasing numbers of HTx candidates with PH [3].
In the early postoperative phase, the allograft right
ventricle (RV) often has difficulties to adapt to the pulmonarySurgery. Published by Elsevier B.V. All rights reserved.
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2.1. Study design
2.1.1. Inclusion and exclusion
This study was approved by the local Ethics Committee
(study number 120/2002).
The inclusion protocol demanded a posttransplant time
interval 2 years, right heart catheterisation before HTx, at
1 year and 2 years posttransplant, and at study inclusion, as
well as the absence of  moderate tricuspid regurgitation.
Sixty-six HTx recipients were screened after informed
consent. Thirteen patients were not included because of
claustrophobia (n = 11), or implanted pacemakers (n = 2). To
test for the introduction of a selection bias due to the
exclusion of patients <2 years posttransplant, we analysed
the survival of all HTx recipients (n = 85) transplanted at our
centre during the same period of time.
2.1.2. Pretransplant treatment
In HTx candidates without PH, 24 patients had developed
end-stage heart failure on the basis of ischaemic heart
disease. Of these, 18 patients had been treated with bypass
surgery, six cases received mitral valve reconstruction in
addition. In HTx candidates with PH, six patients had
developed end-stage heart failure on the basis of ischaemic
heart disease. Four of these patients were treated with
bypass surgery, in two cases in combination with mitral valve
reconstruction. At transplantation, two patients in group 1
were on left ventricular assist device support, while one
patient had been implanted in group 2.
At the time of HTx, all recipients were on optimal heart
failure treatment. Diuretic treatment was adapted indivi-
dually, based on the patient’s documentation of body weight
and regular control of the hepato-jugular reflux.
2.1.3. Postoperative treatment
All HTx recipients received in the intra- and immediate
postoperative phase continuous NO inhalation. NO was
titrated to achieve a low pulmonary artery pressure and
was usually weaned over several hours before extubation. If
tapering of NO was associated with an increase in pulmonary
artery pressure, iloprost inhalations were started and
titrated to maintain low pulmonary artery pressures. In
general, treatment aimed at a balanced fluid management.
Study patients received immunosuppressive medication
(cyclosporine, tacrolimus, azathioprine, mycophenolate
acid, sirolimus, and prednisone) guided by side effects and
regular histological monitoring of RVendomyocardial biopsies
(postoperative weeks 1—4: every week; months 2—6: every
2—4 weeks; months 7—12: every 4—6 weeks; 2nd year: every
2—3 months; 3rd year: every 4 months; 4th/5th year: every 6
months; thereafter: once annually). In general, immunosup-
pression was started with a combination of cyclosporine,
azathioprine and prednisone. Episodes of rejection resulted
in modification of immunosuppressive therapy. Severe,
haemodynamically relevant allograft rejection was not
observed.
Antihypertensive treatment always targeted a blood
pressure of 140/90 mmHg at rest.2.1.4. Study group definition
Participants were stratified by the presence of pretrans-
plant PH into group I without PH (PVR <2.5 Wood units) and
group II with PH (PVR 2.5 Wood units) [5,10,11,16].
2.1.5. Measurements
2.1.5.1. Transthoracic echocardiographic measurements of
graft RV function. Posttransplant echocardiograms were
performed on a regular basis (postoperative weeks 1—4:
every week; months 2—6: every other week; months 7—12:
every 4 weeks; 2nd year: every 2—3months; 3rd year: every 4
months; 4th/5th year: every 6 months; thereafter: once
annually), or as clinically indicated. Acute RV graft dysfunc-
tion was diagnosed when the biplane RV to LV end-diastolic
area ratio was >0.6 [17]. All postoperative echocardiograms
were included in the analysis. All episodes of acute RV
dysfunction (n = 9) occurred within the first two post-
operative years, and resolved with diuretic treatment
(n = 9), and additional inhalation of iloprost in four cases.
2.1.5.2. Cardiac catheterisation. Haemodynamic data were
obtained from pretransplant catheterisation (range: 16—194
days before transplantation), and annual routine catheter-
isations thereafter. Pretransplant reversibility was tested
when PVR was 3 Wood units. Reversibility testing started
with oxygen inhalation and was continued with nitric oxide
inhalation (up to 80 parts per million, n = 2) or prostacyclin
infusion (up to 10 ng/kg min, n = 1) when PVR remained
3 Wood units with oxygen. Cardiac output was determined
by oxymetry (Fick principle).
2.1.5.3. Collagen content. The collagen content in septal
biopsies is representative for ventricular fibrosis in the
human heart [18]. Collagen constitutes by far the largest part
of the extracellular matrix, and, its quantity was assessed as
a surrogate for the extracellular matrix, similar to other
reports [18,19]. In this study, routine septal biopsies of study
participants obtained at transplantation and during follow-
up were analysed. Sections of septal biopsies were stained
with Masson’s Trichrome [19], and the collagen content was
measured by quantitative morphometry with an automated
image analysis system (Leitz DMRB microscope using an
objective PL Fluotar 20 lens coupled to a Pixelink PL-A662
high-resolution colour camera interfacing with Image-Pro
Plus 5.1 software). Measurements were performed by an
investigator blinded to clinical data.
2.1.5.4. CMR examination. Patients were examined supine
using a 1.5 T whole body clinical MR system (Magnetom
Sonata, Siemens Medical Solutions, Erlangen, Germany),
with a six-channel phased array cardiac coil placed around
their chest. Cardiac synchronisation was obtained from three
electrodes placed on the left anterior hemithorax. The
cardiac short axis was determined using three scout images: a
mid-ventricular axial view, a cine breath-hold vertical long
axis, and a cine breath-hold horizontal long axis. The basal
short axis slice was positioned beyond the level of the mitral
valve plane and the ventricles were imaged from the base
towards the apex during short end expiratory breath-holds
using contiguous short axis slices in 8 mm increments.
Complete coverage of the ventricles with the short axis
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state free precession technique (TR/TE/flip 24/1.5/65; slice
thickness 8 mm; temporal resolution 25 ms) was used.
2.1.5.5. CMR image analysis. All analyses were done off-line
in random order by experienced observers blinded to clinical
data. Image analysis was carried out on a dedicated
workstation using commercially available software (Argus
version VA50C, 2002, Siemens Medical Solutions, Erlangen,
Germany). In each cine short axis view, the end-diastolic
image was chosen at the beginning of the QRS complex as the
phase with the largest intraventricular area. End-systolic
images were chosen as the phase with the smallest
intraventricular area. End-diastolic and end-systolic endo-
myocardial borders were manually traced for each slice.
From the area within the contours and the slice thicknessTable 1
Demographic and clinical characteristics of study groups.
All patients
Number (%) 53
Demographics
Time on waiting list (months) 5.9  6
Age at HTx (years) 51  13
Donor age (years) 37  14
Time posttransplant (years) (mean) (range in years) 5.1  2.7 (2.0—8
Etiology of CHF
Ischaemic cardiomyopathy (%) 57
Measurements at HTx
Recipient body weight (kg) 75  12
Donor body weight (kg) 74  11
Recipient/donor body mass index 1.0  0.3
Risk factors
Diabetes (%) 26
Body mass index (BMI) 25  4
Dyslipidemia (%) 15
Number of  moderate rejection episodes 1.76  2.01
Mean allograft rejection score (ISHLT) 1.3  1.4
Immunosuppressive medication
Cyclosporine
Days on cyclosporine 1710
Total dose of cyclosporine (g) 331493
Tacrolimus
Days on tacrolimus 744
Total dose of tacrolimus (g) 5087
Azathioprine
Days on azathioprine 883
Total dose of azathioprine (g) 59640
Mycophenolate
Days on mycophenolate 972
Total dose of mycophenolate (g) 2421013
Sirolimus
Days on sirolimus 634
Total dose of sirolimus (mg) 2287
Prednisone
Days on prednisone 1605
Total dose of prednisone (mg) 13713
Other medication
Diuretics (%) 79
b-Blocker (%) 38
Calcium antagonist (%) 94
ACE-I/ARB (%) 64(8 mm), the evaluation program automatically determined
RV end-diastolic volume (RVEDV) and RV end-systolic volume
(RVESV), according to modified Simpson’s rule (disk summa-
tion, no geometrical assumption). The difference between
RVEDV and RVESV represents the stroke volume (SV). RV
ejection fraction (RVEF) was calculated as (RVEDV  RVESV)/
RVEDV  100. Tables 3 and 4 provide measurements indexed
to body surface area.
2.1.6. Clinical data
Clinical and donor specific data were obtained from chart
review.
2.1.7. Statistical analysis
Measurements and clinical parameters are expressed as
mean values 1 standard deviation (SD), or numbers andPVR <2.5 Wood units PVR 2.5 Wood units p
37 (70) 16 (30)
6.4  6.9 5  4 0.43
50  13 53  12 0.45
37  14 37  15 0.95
.9) 5.2  2.9 (2.1—8.9) 4.9  2.2 (2.0—8.1) 0.70
66 36 0.28
76  11 72  14 0.36
75  10 71  11 0.19
1.1  0.2 1.0  0.3 0.61
19 43 0.09
26  4 24  3 0.21
15 14 0.97
1.57  1.82 2.19  2.37 0.31
1.4  1.4 1.3  1.3 0.86
1674 1791 0.65
328993 336694 0.87
688 838 0.71
3828 7185 0.27
809 1026 0.43
52363 73708 0.27
911 1,011 0.37
2295487 2683,477 0.51
794 236 0.36
2722 1200 0.65
1588 1643 0.79
13970 13153 0.67
70 100 0.42
27 60 0.51
92 100 0.50
64 64 0.98
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Table 2
Haemodynamic parameters pre- and posttransplant.
All patients PVR <2.5 Wood units PVR 2.5 Wood units p
Number (%) 53 37 (70) 16 (30)
Pretransplant
Interval of PVR measurement to HTx, days HTxHTx 95  75 93  82 101  64 0.73
Mean PA (mmHg) 30  13 24  10 43  9 <0.001
Mean PCW (mmHg) 21  10 18  10 30  6 <0.001
Mean transpulmonary gradient (mmHg) 8.5  4.4 6.5  2.8 12.8  4.3 <0.001
Mean PVR (Wood units) 2.3  1.6 1.5  0.6 4.1  1.7 <0.001
1-year posttransplant
RVEDP (mmHg) 4.4  2.9 4.1  2.9 5.1  3.1 0.31
PA systolic (mmHg) 24.1  8.3 22.6  7.8 28.9  7.9 0.04
Mean PA (mmHg) 16  5 15  5 18  6 0.09
Mean PCW (mmHg) 9  5 9  4 10  6 0.34
Mean transpulmonary gradient (mmHg) 6.9  2.9 6.5  2.9 7.7  2.8 0.17
Mean PVR (Wood units) 1.2  0.5 1.2  0.5 1.3  0.5 0.27
Posttransplant at CMR
RVEDP (mmHg) 4.4  3.0 4.6  2.7 4.1  3.7 0.61
PA sys (mmHg) 23.4  7.3 23.4  7.7 24.2  6.3 0.69
Mean PA (mmHg) 16  5 16  5 15  5 0.85
Mean PCW (mmHg) 8  4 8  4 7  4 0.60
Mean transpulmonary gradient (mmHg) 7.6  3.0 7.6  2.9 7.7  3.3 0.90
Mean PVR (Wood units) 1.2  0.5 1.2  0.5 1.3  0.5 0.43
Episodes of acute RV dysfunction (% patients) 17 11 31 0.07percentages, as appropriate. Normally distributed contin-
uous variables were compared by a one-way analysis of
variance (ANOVA). For non-normally distributed variables
comparison was done using Mann—Whitney-U testing. For
comparison of categorical variables chi-square testing or
Fisher’s exact test was performed, as appropriate. The
cumulative survival rates were estimated using the Kaplan—
Meier method, differences in survival curves were compared
with the two-sided log-rank test. Differences were con-
sidered significant at a p-value of <0.05.3. Results
3.1. Clinical characteristics
Pretransplant demographics, risk factors, as well as
measurements at HTx, or medication posttransplant were
not different between the study groups (Table 1).
3.2. Survival analysis of the HTx cohort transplanted in
the same time interval at the local centre
Overall survival of orthotopic HTx recipients trans-
planted in the same time interval (n = 85) at the local
centre as the study patients was 84% after the first year,
79% after 5 years, and 72% after 10 years. Log-rank analysis
revealed no significant difference when comparing the
survival of HTx recipients with or without pretransplant PH
(n = 24 vs n = 61 patients, p = 0.073). In detail, 30 day
survival: 75% vs 92%; 1 year survival: 73 vs 88%; 5 years
survival: 68 vs 84%; 10 years survival: 60 vs 76%. In
addition, RV graft failure related mortality was not
different at 30 days and 1 year posttransplant (p always
0.38).3.3. Haemodynamic characteristics of study patients
with pretransplant PH
Of the 16 patients included, eight presented with mild PH
(PVR2.5 and<3.5 Wood units), five with moderate PH (PVR
3.5 and <5 Wood units), and 3 with severe PH (PVR
5 Wood units) of recent onset. Pretransplant, mean
pulmonary artery pressure (PA), transpulmonary gradient
(TPG) and pulmonary wedge pressure (PCW) were higher ( p
always <0.001) in HTx recipients with PH. One year
posttransplant, only systolic PA remained elevated
(28.9  7.9 vs 22.6  7.8 mmHg, p = 0.04) in these patients.
At study inclusion, pulmonary haemodynamics were no
longer different between groups (Table 2).
3.4. Echocardiographic measurements of graft end-
diastolic LV/RV ratio
The incidence of episodes with acute RV dysfunction was
by trend higher in HTx recipients with pretransplant PH (31%
vs 11% of study patients, p = 0.07). (Table 2)
3.5. RV CMR characteristics
Indexed end-diastolic and end-systolic RV volumes, and RV
ejection fraction were not different between groups. In
group II patients, heart rate was lower (77  9 vs
86  13 bpm; p = 0.032) as well as cardiac output
(6.9  1.5 vs 5.6  1.3; p = 0.01) (Table 3).
In addition, the dependency of RV size and systolic
function on the time interval posttransplant was explored.
The study groups were subdivided by the median time
interval posttransplant (5 years). In HTx recipients with
pretransplant PH, indexed graft RV stroke volume was lower
in the time interval 2—5 years after surgery (38  9 vs
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Table 3
CMR LV and RV measurements.
All patients PVR <2.5 Wood units PVR 2.5 Wood units p
Number (%) 53 37 (70) 16 (30)
CMR LV parameters
LVEDVI (ml/m2) 66  16 68  15 63  17 0.30
LVESVI (ml/m2) 25  8 25  7 25  9 0.78
LVSVI (ml/m2) 41  11 44  11 38  10 0.07
LV ejection fraction (%) 63  7 64  6 60  8 0.19
Heart rate (beats per min) 83  13 86  13 77  9 0.03
LV cardiac output (l/min) 6.5  1.6 6.9  1.5 5.6  1.3 0.01
CMR RV parameters
RVEDVI (ml/m2) 71  17 73  18 67  16 0.23
RVESVI (ml/m2) 28  9 28  9 29  9 0.80
RVSVI (ml/m2) 43  11 45  11 38  9 0.07
RV ejection fraction (%) 61  8 61  8 59  8 0.47
RV cardiac output (l/min) 6.7  1.7 7.1  1.7 5.6  1.3 0.01
Table 4
CMR LV and RV measurements in patients 2—5 and >5 years posttransplant.
PVR <2.5 Wood units PVR 2.5 Wood units p PVR <2.5 Wood units PVR 2.5 Wood units p
Time interval post-HTx (years) 2—5 2—5 >5 >5
Number 26 9 11 7
CMR LV parameters
LVEDVI (ml/m2) 71  15 65  18 0.46 68  13 67  17 0.91
LVESVI (ml/m2) 25  6 28  11 0.53 26  7 23  8 0.56
LVSVI (ml/m2) 45  12 36  9 0.05 42  8 43  11 0.79
LV ejection fraction (%) 35  6 32  6 0.2 33  5 34  4 0.75
Heart rate (beats per min) 86  14 74  9 0.01 87  11 81  8 0.32
LV cardiac output (l/min) 7  1.5 4.9  0.9 0.003 6.8  1.4 6.6  1.1 0.92
CMR RV parameters
RVEDVI (ml/m2) 76  22 68  17 0.33 77  17 65  16 0.21
RVESVI (ml/m2) 29  13 31  10 0.79 32  8 23  7 0.05
RVSVI (ml/m2) 47  13 38  9 0.04 45  11 42  11 0.66
RV ejection fraction (%) 34  7 30  6 0.18 31  4 34  4 0.26
RV cardiac output (l/min) 7.3  1.8 5  1 0.001 7.3  1.7 6.4  1.2 0.32
Fig. 1. Collagen content in graft RV endomyocardial biopsies. Bar graphs
represent the collagen content 1 standard deviation in HTx recipients with
pretransplant PVR<2.5 Wood units and PVR2.5 Wood units, 2—5 years or5
years (y) post-HTx, respectively47  13 ml/m2, p = 0.048). No difference remained between
groups more than 5 years after transplantation (45  11 vs
42  11 ml/m2; p = 0.66) (Table 4).
3.6. Collagen content of endomyocardial biopsies
Collagen content was not different in RV biopsies obtained
pre-implantation and at study inclusion. Likewise, no
differences were observed when the study groups were
subdivided by the median of the posttransplant interval
(Fig. 1).4. Discussion
The major finding of this study is that allograft RV size and
systolic function long-term posttransplant is similar in HTx
recipients with normalised pretransplant PH and in HTx
recipients with normal pulmonary artery pressure pretrans-
plant. This finding is important in the context of the
increasing numbers of HTx candidates with pulmonary
hypertension.
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The hypothesis that allograft RV size and systolic function
may normalise late after HTx in recipients with pretransplant
PH was tested using a cross-sectional study design in a local
HTx cohort. Several reports indicate that normalisation of
pretransplant PH occurs within the first two postoperative
years [10,12]. Therefore, this study included HTx recipients
who were2 years after transplantation. In accordance with
the literature, pretransplant PH had resolved incompletely in
our study patients 1 year posttransplant. At study inclusion,
however, pulmonary haemodynamics were no longer differ-
ent between HTx recipients with or without pretransplant
PH. While this reflects the adequacy of the inclusion criterion
in this regard, studying HTx recipients who survived the first 2
years posttransplant might select patients with a better
outcome per se, which might limit the significance of this
study. Survival was not different in a Kaplan—Meier survival
analysis which included all HTx recipients grafted in the same
period of time at our centre whether presenting with or
without pulmonary hypertension. On this basis we can
exclude the introduction of relevant a selection bias.
4.2. Pulmonary haemodynamics and graft RV function
Acute dysfunction of the graft RV is one of the major
concerns in the early postoperative course after HTx. Usually,
acute graft RV failure is reported on the basis of clinical
diagnosis [8—10]. This study records RV dysfunction based on
echocardiographic diagnosis, which may explain the higher
incidence of episodes with acute RV dysfunction reported
here [10]. Clinically, most cases of acute RV dysfunction in
our study participants resolved with intensified diuretic
treatment suggesting that adequate fluid management
supports the adaptation of the graft RV to the recipient’s
pulmonary circulation.
Graft RV size and systolic function were assessed by CMR
which is most accurate for RV assessments [22]. Long-term
after HTx, graft RV size and systolic function was not
different whether PH had been present or absent pretrans-
plant. This observation corresponds with previous imaging
studies, which had studied allograft RV size and volumes in
HTx recipients long-term posttransplant [20,23], but had not
stratified for pretransplant PH. In this study population, RV
systolic function did not recover in parallel with the
normalisation of pulmonary artery pressures, as RV stroke
volumes were lower in HTx recipients with pretransplant PH
who were 2—5 years after HTx when compared to those with
an interval of more than 5 years posttransplant. Several
factors may be relevant for this transitory decreased systolic
function in these patients; however, the collagen content
should not play a relevant role as it was not different when
measured in biopsies taken at HTx and in HTx recipients with
pretransplant PH who were 2—5 years after HTx.
4.3. Limitations
Limitations of this study are the smaller number of
patients included and its cross-sectional design; however, to
our knowledge, this is the largest CMR study on graft RV
function. Furthermore, this study lacks serial measurementsof graft RV size and function, which may provide additional
information; [15] however, the principal finding of this study
remains.Contributors
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